The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:2214-2218 May 24, 2007 Number 21
NextNext

Posaconazole Prophylaxis in Hematologic Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Ullmann, A. J.
-Related Article
by Cornely, O. A.
-PubMed Citation
To the Editor: Ullmann et al. and Cornely et al. (Jan. 25 issue)1,2 report on posaconazole prophylaxis in patients with hematologic cancers. Ullmann et al. found that posaconazole was superior to fluconazole for protection against invasive aspergillosis, and Cornely et al. found that posaconazole was superior to fluconazole and also to itraconazole in preventing fungal infections. After the widespread use of fluconazole and voriconazole as prophylaxis3 and antifungal treatment, an increase in the risk of infections with resistant fungi was observed.4,5 Selection pressure due to continuous exposure to azoles appears to play a crucial role in the emergence of resistance . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.